Pelthos Therapeutics Stock Forward View
| PTHS Stock | 24.50 1.25 5.38% |
Momentum
Sell Peaked
Oversold | Overbought |
This summary links Pelthos Therapeutics' attention patterns to recent price behavior and peer context.
The Naive Prediction forecasted value of Pelthos Therapeutics on the next trading day is expected to be 24.52 with a mean absolute deviation of 1.04 and the sum of the absolute errors of 63.14.Pelthos Therapeutics after-hype prediction price | $ 24.96 |
The module provides attention context in addition to forecasting models, technical indicators, analyst estimates, and earnings trends.
Use Historical Fundamental Analysis of Pelthos Therapeutics to cross-verify projections for Pelthos Therapeutics. The view supplies historical context for the projection discussion.Pelthos Therapeutics Additional Predictive Modules
Most predictive techniques to examine Pelthos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Pelthos using various technical indicators. When you analyze Pelthos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Pelthos Therapeutics Cash Forecast
Cash flow forecasting for Pelthos Therapeutics combines time-series analysis with quantitative techniques to identify recurring patterns in Pelthos Therapeutics' financial data that may predict future operating performance.
Cash | First Reported 2010-12-31 | Previous Quarter 590.5 K | Current Value 620 K | Quarterly Volatility 223.9 K |
Macro event markers
Naive Prediction Price Forecast For the 16th of March 2026
Given 90 days horizon, the Naive Prediction forecasted value of Pelthos Therapeutics on the next trading day is expected to be 24.52 with a mean absolute deviation of 1.04 , mean absolute percentage error of 1.90 , and the sum of the absolute errors of 63.14 .Please note that although there have been many attempts to predict Pelthos Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Pelthos Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Pelthos Therapeutics | Pelthos Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Pelthos Therapeutics uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Pelthos Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Pelthos Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 118.7507 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 1.0351 |
| MAPE | Mean absolute percentage error | 0.0434 |
| SAE | Sum of the absolute errors | 63.1437 |
Experienced investors tracking Pelthos Therapeutics' watch for mean reversion setups: periods when price has deviated significantly from its long-run average, creating an asymmetric risk-reward profile for patient capital.
After-Hype Price Density Analysis
The after-hype price distribution for Pelthos Therapeutics reflects the range of predicted outcomes based on historical news impact analysis. The spread of Pelthos Therapeutics' distribution is a direct measure of the uncertainty inherent in any forward-looking price model.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The after-hype price boundaries for Pelthos Therapeutics are calculated from a database of Pelthos Therapeutics' historical headline events and subsequent daily price movements. Pelthos Therapeutics' after-hype downside and upside margins for the prediction period are 19.26 and 30.66, respectively. Investors should treat these as statistical reference points, not precise predictions for Pelthos Therapeutics.
Current Value
The after-hype framework applied to Pelthos Therapeutics assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Pelthos Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pelthos Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Pelthos Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.31 | 5.70 | 0.46 | 0.03 | 3 Events | 6 Events | In 3 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
24.50 | 24.96 | 1.88 |
|
Hype Timeline
Pelthos Therapeutics is at this time traded for 24.50. The company has historical hype elasticity of 0.46, and average elasticity to hype of competition of -0.03. Pelthos is forecasted to increase in value after the next headline, with the price projected to jump to 24.96 or above. The average volatility of media hype impact on the company the price is over 100%. The price appreciation on the next news is forecasted to be 1.88%, whereas the daily expected return is at this time at 0.31%. The volatility of related hype on Pelthos Therapeutics is about 6705.88%, with the expected price after the next announcement by competition of 24.47. Net Loss for the year was -7.96 M with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next forecasted press release will be in 3 days. Use Historical Fundamental Analysis of Pelthos Therapeutics to cross-verify projections for Pelthos Therapeutics. The view supplies historical context for the projection discussion.Related Hype Analysis
Peer hype analysis for Pelthos Therapeutics aggregates sentiment and news impact data from Pelthos Therapeutics' competitive set to identify sector-wide trends before they are fully reflected in Pelthos Therapeutics's own price.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CASI | CASI Pharmaceuticals | 0.04 | 8 per month | 0.00 | -0.12 | 11.90 | -8.51 | 98.17 | |
| LSTA | Lisata Therapeutics | 0.03 | 6 per month | 1.01 | 0.17 | 8.21 | -3.12 | 93.60 | |
| CLSD | Clearside Biomedical | -0.72 | 2 per month | 0.00 | -0.26 | 7.96 | -17.54 | 83.67 | |
| KAPA | Kairos Pharma | -0.03 | 5 per month | 0.00 | -0.08 | 10.26 | -8.24 | 29.57 | |
| LEXX | Lexaria Bioscience Corp | 0.02 | 9 per month | 0.00 | -0.04 | 10.61 | -12.05 | 42.53 | |
| PASG | Passage Bio | -0.12 | 7 per month | 0.00 | -0.02 | 8.68 | -9.87 | 58.13 | |
| LIXT | Lixte Biotechnology Holdings | -0.04 | 9 per month | 0.00 | -0.06 | 10.20 | -6.85 | 22.37 | |
| ENLV | Enlivex Therapeutics | 0.08 | 6 per month | 4.31 | 0.01 | 8.33 | -7.27 | 18.55 | |
| MTVA | MetaVia | -0.17 | 9 per month | 0.00 | -0.29 | 8.76 | -17.75 | 52.65 | |
| CING | Cingulate | 0.06 | 7 per month | 3.81 | 0.25 | 9.68 | -6.53 | 24.88 |
Other Forecasting Options for Pelthos Therapeutics
Investors evaluating Pelthos at any level of experience must contend with the challenge of understanding Pelthos Therapeutics' price movement. The presence of noise in Pelthos Stock price charts can significantly complicate investment decisions.Pelthos Therapeutics Related Equities
The following equities are related to Pelthos Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Pelthos Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Pelthos Therapeutics Market Strength Events
For investors tracking Pelthos Therapeutics, market strength indicators offer a quantitative way to evaluate how the stock behaves under varying market conditions. These metrics are widely used to refine market timing and identify the most favorable moments to trade Pelthos Therapeutics.
Pelthos Therapeutics Risk Indicators
Analyzing Pelthos Therapeutics' basic risk indicators provides investors with a structured view of the risk-return trade-off associated with pelthos stock. Forecasting Pelthos Therapeutics' future price accurately requires understanding and quantifying the risks present in the investment.
| Mean Deviation | 4.28 | |||
| Semi Deviation | 5.03 | |||
| Standard Deviation | 5.66 | |||
| Variance | 32.02 | |||
| Downside Variance | 27.59 | |||
| Semi Variance | 25.29 | |||
| Expected Short fall | -4.87 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Pelthos Therapeutics
Coverage intensity for Pelthos Therapeutics matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Pelthos Therapeutics Short Properties
Short sentiment tied to Pelthos Therapeutics matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 587.6 K | |
| Cash And Short Term Investments | 513.4 K |
Additional Tools for Pelthos Stock Analysis
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |